Paul Fehlner is Head of Intellectual Property, Novartis Pharma. In this role, he leads the team responsible for obtaining and enforcing intellectual property rights for Pharma’s products. The team acts as “IP Architects,” working to build a holistic IP portfolio. This includes patents, trademarks, name creation, regulatory exclusivities and other intellectual property rights.
Paul joined Novartis in 2008 from the law firm of Baker Botts, where he specialized in intellectual property counseling and strategic planning in the pharmaceutical, biotechnology and medical device industries. Paul started his career in IP law in 1990 as a Law Clerk in the biotech and pharmaceutical group at Pennie & Edmonds. His career includes seven years as a partner at Darby & Darby, with earlier work as biotechnology counsel for Rhone-Poulence Rorer, and as associate for the boutique IP firm of Klauber & Jackson. In 2015, IAM (Intellectual Asset Magazine) named him one of the World’s Leading IP Strategists.
Paul has a B.S. in Chemistry from Haverford College (high honors; Phi Beta Kappa), a Ph.D. in Immunology and Biochemistry from The Rockefeller University (Lois P. Markey Fellow), and a J.D. from Fordham University School of Law.